BACTROBAN CREAM

Država: Kanada

Jezik: engleski

Izvor: Health Canada

Kupi sada

Preuzimanje Svojstava lijeka (SPC)
11-02-2017

Aktivni sastojci:

MUPIROCIN (MUPIROCIN CALCIUM)

Dostupno od:

GLAXOSMITHKLINE CONSUMER HEALTHCARE ULC

ATC koda:

D06AX09

INN (International ime):

MUPIROCIN

Doziranje:

2%

Farmaceutski oblik:

CREAM

Sastav:

MUPIROCIN (MUPIROCIN CALCIUM) 2%

Administracija rute:

TOPICAL

Jedinice u paketu:

15G

Tip recepta:

OTC

Područje terapije:

ANTIBIOTICS

Proizvod sažetak:

Active ingredient group (AIG) number: 0117081001; AHFS:

Status autorizacije:

CANCELLED POST MARKET

Datum autorizacije:

2020-07-24

Svojstava lijeka

                                _ _
_Product Monograph: _
_July 6, 2016_
_ _
_Page 1 of 28_
PRODUCT MONOGRAPH
BACTROBAN
® CREAM
Mupirocin Cream USP 2% (w/w) as mupirocin calcium
TOPICAL ANTIBIOTIC
GlaxoSmithKline Consumer Healthcare Inc
7333 Mississauga Road North
Mississauga, Ontario
L5N 6L4
Date of Preparation:
July 6, 2016
Submission Control No: 194464
® Bactroban is a registered trademark, used under license by
GlaxoSmithKline Consumer Healthcare Inc.
_ _
_Product Monograph: _
_July 6, 2016_
_ _
_Page 2 of 28_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................5
DRUG INTERACTIONS
....................................................................................................7
DOSAGE AND ADMINISTRATION
................................................................................7
OVERDOSAGE
..................................................................................................................8
ACTION AND CLINICAL PHARMACOLOGY
..............................................................8
STORAGE AND STABILITY
..........................................................................................10
SPECIAL HANDLING INSTRUCTIONS
.......................................................................10
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................10
PART II: SCIENTIFIC INFORMATION
...............................................................................11
PHARMACEU
                                
                                Pročitajte cijeli dokument
                                
                            

Dokumenti na drugim jezicima

Svojstava lijeka Svojstava lijeka francuski 24-08-2016

Upozorenja za pretraživanje vezana za ovaj proizvod

Pogledajte povijest dokumenata